Characteristic | Study cohort |
---|---|
With > 2 months of follow-up to allow for treatment | |
N | 285 |
% | 87.7% |
Receiving surgery within 4 months of diagnosis | |
N | 110 |
% | 38.60% |
Receiving radiation within 4 months of diagnosis | |
N | 91 |
% | 31.93% |
Receiving any medication | |
N | 212 |
% | 74.4% |
Type of treatment received (at any time post-index) | |
Chemotherapy alone | 15.1% |
Aromatase Inhibitors (AI) therapy | |
Anastrazole monotherapy | 11.8% |
Letrozole monotherapy | 9.4% |
Exmenestane monotherapy | 1.4% |
Multiple AI therapies | 2.4% |
Non-AI therapy | |
Fulvestrant monotherapy | 4.2% |
Tamoxifen monotherapy | 1.9% |
Toremifene monotherapy | 0.0% |
Megestrol monotherapy | 0.9% |
Multiple non-AI therapies | 0.5% |
Chemotherapy combined with AI therapy | 11.8% |
Chemotherapy combined with non-AI therapy | 15.1% |
AI therapy combined with non-AI therapy | 10.4% |
Chemotherapy combined with AI and non-AI therapy | 15.1% |
Duration of any treatment (months) | |
Mean ± SD | 12.9 ± 9.1 |
Median | 11.0 |
Duration of AI treatment (months), among those with any AI use | |
Mean ± SD | 11.0 ± 8.1 |
Median | 9.5 |
Duration of non-AI treatment (months), among those with any non-AI use | |
Mean ± SD | 5.6 ± 5.4 |
Median | 4.0 |
Duration of chemo treatment (months), among those with any chemo use | |
Mean ± SD | 8.5 ± 7.2 |
Median | 6.0 |